论文部分内容阅读
目的观察重组人血管内皮抑制素联合以铂类为基础的术后辅助化疗用于非小细胞肺癌(NSCLC)患者术后治疗的临床疗效及不良反应。方法回顾性分析117例ⅠB至ⅢA期NSCLC患者术后,分别接受重组人血管内皮抑制素联合以铂类为基础方案辅助化疗(观察组)和单纯铂类方案化疗(对照组)治疗。评估治疗方案对患者无病生存期(DFS)的影响,同时记录两组毒副反应发生情况。结果ⅢA期患者观察组中位DFS为29.0个月,较对照组16.0个月延长13.0个月,组间差异具有统计学意义(P=0.015)。两组不良反应发生率差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素联合以铂类为基础方案辅助化疗能延长ⅢA期NSCLC患者术后DFS,且安全性良好。
Objective To observe the clinical efficacy and adverse reactions of recombinant human endostatin combined with platinum-based postoperative adjuvant chemotherapy for postoperative treatment of patients with non-small cell lung cancer (NSCLC). Methods A total of 117 NSCLC patients with stage ⅠB to ⅢA were retrospectively analyzed. The patients were treated with recombinant human endostatin combined with platinum - based adjuvant chemotherapy (observation group) and platinum - based chemotherapy alone (control group). Assess the impact of treatment regimen on patients with disease-free survival (DFS), and record the occurrence of two groups of side effects. Results The median DFS of patients in stage Ⅲ A was 29.0 months, which was 13.0 months longer than that of control group (16.0 months). The difference between the two groups was statistically significant (P = 0.015). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Recombinant human endostatin combined with platinum-based adjuvant chemotherapy can prolong the postoperative DFS of patients with stage Ⅲ A NSCLC and is safe.